Join to view full profile
5841 S. MARYLAND AVENUEM/C 2115Chicago, IL 60637
Phone+1 773-702-9297
Fax+1 773-702-0963
Dr. Bishop is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Bishop is an oncologist based in Chicago, IL, specializing in hematologic oncology. He completed his medical education and training at the University of Illinois College of Medicine, McGaw Medical Center of Northwestern University, and Loyola University Medical Center. Dr. Bishop currently serves as the Director at The David and Etta Jonas Center Cellular Therapy at the University of Chicago Medical Center and has held several leadership roles in oncology research and practice. His research experience includes extensive work in areas such as amyloidosis, non-Hodgkin lymphoma, and hematologic oncology. Dr. Bishop has contributed to multiple publications in reputable journals and has been involved in clinical trials as a principal investigator, focusing on CAR T-cell therapy and other cancer treatments.
Clinical Expertise
- Amyloidosis, Non-Hodgkin lymphoma, Hematologic oncology, Myelodysplasia, Myelofibrosis, Hematopoietic stem cell transplantation, Multiple myeloma, Lymphoma, Stem cell transplantation, Leukemia, Adoptive immunotherapy, Cellular Therapy, Myelodysplastic syndromes , Bone marrow transplantation, Oropharyngeal lymphoma, Angiocentric lymphoma, Acute myeloid leukemia
Education & Training
Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1986 - 1988- McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1985 - 1986
University of Illinois College of MedicineClass of 1985
University of Illinois at Urbana-ChampaignB.S., Biology - Ecology, Ethology, and Evolution, 1981
Certifications & Licensure
IL State Medical License 1986 - 2029
NE State Medical License 1992 - 2028
WI State Medical License 2011 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Included in Castle Connolly America's Top Doctors (Medical Oncology) 2013-2026
- Included in The Best Doctors in America, National 2001-2003, 2007-2009, 2011-2021
- Fellow, American Society fo Clincial Oncology (FASCO) American Society of Clinical Oncology, 2018
Clinical Trials
- Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation Start of enrollment: 2017 Feb 08
- Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma Start of enrollment: 2019 Dec 23
- TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) Start of enrollment: 2018 Dec 19
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients.Vincenzo J Pizzuti, Angela Dunn, Kathryn Colborn, Mckenzie Schubat, Thomas Althaus
Blood Neoplasia. 2026-11-01 - Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors.E E Dumbrava, D Olson, M A Gouda, M A George, S D Saibil
Annals of Oncology. 2026-10-01 - Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.Erting Tang, Yifei Hu, Guoshuai Cao, Duy-Thuc Nguyen, Nicholas W Asby
Cancer Immunology Research. 2026-08-04
Journal Articles
- High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor ResponsesFowler DH, Mossoba ME, Halverson DC, Kurlander R, Blacklock Schuver B, Carpenter AE, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche JC, Sportes C, ..., Clin Cancer Res, 1/12/2015
- Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipientsYew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y, Bone Marrow Transplant, 1/8/2015
- Symptom distress predicts long-term health and well- being in allogeneic stem cell transplantation survivorsBevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L, Biol Blood Marrow Transplant, 1/1/2014
Books/Book Chapters
Abstracts/Posters
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSMichael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Cellular Immunotherapy Including Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-cells for Hematologic MalignanciesChicago, IL - 1/30/2015
- Immunotherapy: Revolutionizing the Way We Treat Hematologic MalignanciesChampaign, IL - 1/27/2015
Other
- Alternative Donor Sources in Allogeneic Stem Cell Transplantation.Bishop MR, Medscape Oncology
1/1/1998 - Non-Hodgkin's Lymphoma and Autologous Stem Cell Transplantation: A Critical Review.Bishop MR, Bierman PJ, Vose JM, Armitage JO, Revisions en Cancer
1/1/1994 - Discovery--And Implications--Of a Single Human Bone Marrow Stem Cell.Bishop MR, Oncology Bulletin
1/1/1993
Press Mentions
Arcellx Provides Third Quarter 2024 Financial Results and Business HighlightsNovember 7th, 2024
BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-cell Non-Hodgkin LymphomaDecember 20th, 2019
Insurers and Government Are Slow to Cover Expensive CAR-T Cancer TherapyJuly 17th, 2018
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: